# Claim table — ivermectin + mebendazole cancer Reel

| Claim | Source status | PBC read |
|---|---|---|
| “84% of cancer patients” benefited after ivermectin + mebendazole | PubMed abstract reports an 84.4% Clinical Benefit Ratio in a prospective observational cohort, based on self-reported follow-up in 122/197 participants. | Real published abstract, but observational and self-reported; not proof of cure. |
| “Peer-reviewed and published” | PubMed lists Anticancer Research 2026 article. | True in publication-status sense, but the journal issued an Expression of Concern. |
| Cancer disappeared/shrunk/stopped spreading | PubMed abstract says 32.8% self-reported no evidence of disease, 15.6% regression, 36.1% stable disease, 15.6% progression. | Needs medical-record verification; self-report and mixed concurrent therapies are major limitations. |
| “Potential cancer cure” / CIA-suppressed cure framing | Claimed in the Reel transcript. | Not verified by the captured medical record; should be labelled unsupported/conspiracy framing. |
| Ivermectin has anticancer mechanisms | Reviews describe preclinical/in-vitro/animal mechanisms. | Research interest is real; clinical benefit in humans remains unproven without robust RCTs. |
| Safe / zero-risk / horse-paste dosing charts | Earlier source folder shows social dosing-chart claims; MedlinePlus/FDA warn against taking more/other forms without prescription and against animal products. | Do not promote as safe cancer protocol. |